Aubrey Capital Management’s Pfizer PFE Stock Holding History

Aubrey Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,762	Closed	-$407K	–	73
2022 Q1	$407K	Buy	+7,762	New	+$403K	0.23%	44

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aubrey Capital Management's PFE Position: Q2 2022 in Review

Aubrey Capital Management sold out of Pfizer (PFE) in Q2 2022, closing a stake of 7,762 shares — an estimated $407K sold.

Aubrey Capital Management first reported a position in PFE in Q1 2022 and held it in 1 quarter. The position peaked at $407K in Q1 2022. 3,158 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

Aubrey Capital Management reported no remaining Pfizer position as of Q2 2022 after selling out during the quarter.
Aubrey Capital Management sold 7,762 Pfizer shares in Q2 2022, an estimated $407K.
Aubrey Capital Management first reported a position in Pfizer in Q1 2022 and held it in 1 quarter.
Aubrey Capital Management's Pfizer position peaked at $407K in Q1 2022.
3,158 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Aubrey Capital Management's 13F filing for Q2 2022, filed 16 Aug 2022.